Cognitive Impairments in Patients with GHB Use Disorder Predict Relapse in GHB Use.

Autor:	Beurmanjer H; Novadic-Kentron Addiction Care, Vught, The Netherlands.; Nijmegen Institute for Scientist-Practitioners in Addiction (NISPA), Nijmegen, The Netherlands., Bruijnen CJWH; Nijmegen Institute for Scientist-Practitioners in Addiction (NISPA), Nijmegen, The Netherlands., Greeven PGJ; Novadic-Kentron Addiction Care, Vught, The Netherlands.; Nijmegen Institute for Scientist-Practitioners in Addiction (NISPA), Nijmegen, The Netherlands., De Jong CAJ; Novadic-Kentron Addiction Care, Vught, The Netherlands., Schellekens AFA; Nijmegen Institute for Scientist-Practitioners in Addiction (NISPA), Nijmegen, The Netherlands.; Department of Psychiatry, RadboudUmc, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands., Dijkstra BAG; Novadic-Kentron Addiction Care, Vught, The Netherlands.; Nijmegen Institute for Scientist-Practitioners in Addiction (NISPA), Nijmegen, The Netherlands.
Jazyk:	angličtina
Zdroj:	European addiction research [Eur Addict Res] 2022; Vol. 28 (5), pp. 350-357. Date of Electronic Publication: 2022 Jul 19.
DOI:	10.1159/000525507
Abstrakt:	Background: The recreational use of gamma hydroxybutyrate (GHB) is associated with frequent overdoses, coma and the risk of developing GHB use disorder (GUD). Several studies suggest negative effects of GHB use or related comas on cognition. Since relapse rates are high in GUD and cognitive impairment has been associated with relapse in other substance use disorders, we aimed to (1) investigate the prevalence of cognitive impairment before and after detoxification, (2) analyse the relationship between GHB use, comas, and cognitive impairment, and (3) explore the association between cognitive impairment and relapse after detoxification in GUD patients. Methods: In these secondary analyses of a prospective cohort study, a consecutive series of patients with GUD (n = 103) admitted for detoxification were recruited at six addiction care facilities in the Netherlands. The Montreal Cognitive Assessment (MoCA) was used to screen for cognitive impairments before and after detoxification. The follow-up duration for the assessment of relapse in GHB use was 3 months. Results: A substantial number of patients with GUD screened positive for cognitive impairment before (56.3%) and after (30.6%) detoxification. Impairment on the MoCA memory domain was most frequent (58.8%). Cognitive impairment was not related to the severity of GUD or number of GHB-induced comas. Logistic regression analysis showed that only the memory score independently predicted relapse. Discussion: Cognitive impairment seems highly prevalent among patients with GUD, possibly related to the risk of relapse. The absence of a relationship between the severity of GUD, level of GHB use, the number of GHB-induced comas, and cognitive impairment suggest that other factors may also contribute to the observed cognitive impairment. (© 2022 The Author(s). Published by S. Karger AG, Basel.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu